Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells
نویسندگان
چکیده
منابع مشابه
Tissue Factor–Factor VII Complex As a Key Regulator of Ovarian Cancer Phenotypes
Tissue factor (TF) is an integral membrane protein widely expressed in normal human cells. Blood coagulation factor VII (fVII) is a key enzyme in the extrinsic coagulation cascade that is predominantly secreted by hepatocytes and released into the bloodstream. The TF-fVII complex is aberrantly expressed on the surface of cancer cells, including ovarian cancer cells. This procoagulant complex ca...
متن کاملTissue factor-dependent autoactivation of human blood coagulation factor VII.
We recently showed that single-chain zymogen factor VII is converted to two-chain factor VIIa in an autocatalytic manner following complex formation with either cell-surface or solution-phase relipidated tissue factor apoprotein (Nakagaki, T., Foster, D. C., Berkner, K. L., and Kisiel, W. (1991) Biochemistry 30, 10819-10824). We have now performed a detailed kinetic analysis of the autoactivati...
متن کاملActivation of human factor VII in the initiation of tissue factor-dependent coagulation.
We have used activation peptide release assays to compare factor VII and activated factor VII (VIIa) activation of factor X, normal factor IX (IXN), and a variant factor IX (IXBmLE), which, after activation, is unable to back-activate factor VII. In purified systems, factor VII and VIIa each rapidly activated factor X, but after a one minute lag for factor VII. VIIa also readily activated both ...
متن کاملAcquired deficiency of coagulation factor VII
Factor VII (FVII) is found in small amounts in plasma and has a very short half-life in circulation. FVII is vitamin K-dependently synthesized in the liver. As such, hepatopathies, vitamin K deficiency, or use of vitamin K antagonists is the cause of acquired deficiency. Other types of acquired FVII deficiencies are rare.1 Here we describe a case of acquired factor VII deficiency associated to ...
متن کاملFactor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
The overexpression of tissue factor (TF) observed in numerous cancer cells and clinical samples of human cancers make TF an ideal target for cancer therapy. Here, we report an energized fusion protein, hlFVII-LDP-AE, which can be used for cancer therapy and is composed of a human Factor VII light chain (hlFVII) conjugated to the cytotoxic antibiotic lidamycin (LDM, LDP-AE). hlFVII-LDP-AE binds ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Cancer
سال: 2009
ISSN: 0007-0920,1532-1827
DOI: 10.1038/sj.bjc.6605406